Mechanism of anosmia caused by symptoms of COVID-19 and emerging treatments

R Najafloo, J Majidi, A Asghari… - ACS chemical …, 2021 - ACS Publications
The occurrence of anosmia, the loss or change in sense of smell, is one of the most common
symptoms of COVID-19 experienced by almost 53% of those affected. Several hypotheses …

Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis

Z Li, S Niu, B Guo, T Gao, L Wang, Y Wang… - Cell …, 2020 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 …

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

G Lanzoni, E Linetsky, D Correa… - Stem cells …, 2021 - academic.oup.com
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory …

Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: an …

X Xu, W Jiang, L Chen, Z Xu, Q Zhang… - Clinical and …, 2021 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has …

Human gingival mesenchymal stem cells retain their growth and immunomodulatory characteristics independent of donor age

JR Dave, SS Chandekar, S Behera, KU Desai… - Science …, 2022 - science.org
Aging has been reported to deteriorate the quantity and quality of mesenchymal stem cells
(MSCs), which affect their therapeutic use in regenerative medicine. A dearth of age-related …

Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: an in silico analysis

IC Schultz, APS Bertoni, MR Wink - Stem cell reviews and reports, 2021 - Springer
In the end of 2019 COVID-19 emerged as a new threat worldwide and this disease present
impaired immune system, exacerbated production of inflammatory cytokines, and …

Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19

D Sharma, F Zhao - NPJ Regenerative Medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected nearly 118
million people and caused~ 2.6 million deaths worldwide by early 2021, during the …

[HTML][HTML] Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia

A Putra, A Widyatmoko, S Ibrahim, F Amansyah… - …, 2021 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the
outbreak of coronavirus disease 2019 (COVID-19), which has been rapidly spreading …

[HTML][HTML] The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system

GM Ellison-Hughes, L Colley, KA O'Brien… - Frontiers in …, 2020 - frontiersin.org
The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
that causes coronavirus disease 2019 (COVID-19) has led to 47 m infected cases and 1. 2 m …

[HTML][HTML] An overview on the epidemiology and immunology of COVID-19

M Meskini, MR Rami, P Maroofi, S Ghosh… - Journal of Infection and …, 2021 - Elsevier
Coronaviruses are a large family of viruses that cause illnesses ranging from the common
cold to more severe diseases such as Middle East Respiratory Syndrome (MERS), Severe …